overview
The addition of the immunotherapy drug atezolizumab to postoperative chemotherapy is not effective in patients with triple-negative breast cancer who are at high risk of developing metastases.
study details
ALEXANDRA is a clinical trial partnership between Roche, the Breast International Group (BIG), Alliance Foundation Trials (AFT), Institut Jules Bordet (IJB) and Frontier Science.
This is a phase 3, multicentre, randomised, open-label study comparing atezolizumab (anti-PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple negative breast cancer (TNBC).
Title of publication
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer
The ALEXANDRA/IMpassion030 Randomized Clinical Trial
AUTHORS
Michail Ignatiadis, MD; Andrew Bailey, MSc; Heather McArthur, MD; Sarra El-abed, MD;
Evandro de Azambuja, MD; Otto Metzger, MD; Stephen Y. Chui, MD; Max Dieterich, MD; Thomas Perretti, MSc; Esther Shearer-Kang, PhD; Luciana Molinero, PhD; Günther G. Steger, MD; Jacek Jassem, MD; Soo Chin Lee, MD; Michaela Higgins, MD; Jose Zarba, MD; Marcus Schmidt, MD; Henry Gomez, MD; Angel Guerrero Zotano, MD; Luca Moscetti, MD; Joanne Chiu, MD; Elisabetta Munzone, MD; Noa Efrat Ben-Baruch, MD; Emilio Bajetta, MD; Shinji Ohno, MD; Seock-Ah Im, MD; GustavoWerutsky, MD; Einav Nili Gal-Yam, MD; Xavier Gonzalez Farre, MD; Ling-Ming Tseng, MD; William Jacot, MD; Oleg Gluz, MD; Zhimin Shao, MD; Yaroslav Shparyk, MD; Anastasia Zimina, MD; Eric Winer, MD; David A. Cameron, MD; Giuseppe Viale, MD; Shigehira Saji, MD; Richard Gelber, PhD; Martine Piccart, MD
PUBLICATION REFERENCE
Journal of the American Medical Association: doi:10.1001/jama.2024.26886
